A Pound of Prevention? Assessing the Value of New Cholesterol-Lowering Drugs

PCSK9 inhibitors substantially reduce cholesterol levels, but the U.S. Food and Drug Administration–approved PCSK9 inhibitors, alirocumab and evolocumab, came to market priced at $14 000 per year—more than 100 times the cost of a generic statin. Kazi and colleagues' cost-effectiveness analysis of alirocumab in secondary prevention is based on new trial results and updated pricing. The editorialist discusses the findings and what it takes for preventive therapies to be cost-effective.

from A via a.sfakia on Inoreader http://bit.ly/2Sam2PR